The incidence of vasodilation-related events (flushing, headache, dizziness and oedema) was determined in a total of 37,670 patients treated with diltiazem, nicardipine, isradipine or amlodipine and studied by Prescription-Event Monitoring between 1984 and 1991.
Event rates are expressed as the percentage of patients who experienced these events during the six months after the first prescription. The rates for all these events with the newer vasoselective dihydropyridines (nicardipine, isradipine and amlodipine) were higher than those with diltiazem. Among the three dihydropyridines, there were large individual differences in the rates. With nicardipine, the frequency of each of the four vasodilation-related events were similar to one another (≈3%). With isradipine, the rates were also similar to one another but all were approximately twice those measured in the nicardipine study (≈6%). These differences may have been due to confounding factors such as the publicity about adverse drug reactions, the indication for use by individual patients or the doses actually being used at the time the event occurred. With amlodipine, in contrast, the rate for oedema was two to four times larger than the rates for flushing, headache or dizziness.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Chaffman M, Brogden RN (1985) Diltiazem: a review of its pharmacological properties and therapeutic efficacy. Drugs 29:387–4542
Sorkin EM, Clissold SP (1987) Nicardipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 33:296–345
William W, Parmley MD (1990) New calcium antagonists: relevance of vasoselectivity. Am H J 120:1408–1413
Freedman DD, Waters DD (1987) ‘Second generation’ dihydropyridine calcium antagonists: greater vascular selectivity and some unique applications. Drugs 34:578–598
Inman WHW, Rawson NSB, Wilton LV (1986) Prescription-event monitoring. In: Inman WHW (ed) Monitoring for drug safety. 2nd edn. MTP Press, Lancaster, pp 213–235
Rawson NSB, Pearce GL, Inman WHW (1990) Prescription-event monitoring: methodology and recent progress. J Clin Epidemiol 43:509–522
Waller PC, Pearce GL, Rawson NSB, Wilton LV, Inman WHW (1990) Post-marketing surveillance of diltiazem by prescription-event monitoring. Pharmaceut Med 4:319–328
Inman W, Kubota K, Wilton L, Pearce G (1993) PEM report Number 1: Nicardipine. Pharmacoepidemiol Drug Safety 2:259–285
Fitton A, Benfield P (1990) Isradipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 40:31–74
Bremner AD, Fell PJ, Hosie J, James IGV, Saul PA, Taylor SH (1993) Early side-effects of antihypertensive therapy: comparison of amlodipine and nifedipine retard. J Hum Hypertension 7:79–81
Finney DJ (1986) Statistical logic in the monitoring of reactions to therapeutic drugs. In: Inman WHW (ed) Monitoring for drug safety. 2nd edn. MTP Press, Lancaster, pp 423–442
Dahlof B (1989) Hemodynamic response, safety, and efficacy of isradipine in the treatment of essential hypertension. Am J Med 86 [Suppl 4A]:19–26
Murdoch D, Heel RC (1991) Amlodipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 41:478–505
Walker G (1991) ABPI data sheet compendium 1991–92. Datapharm Publications, London, pp 304–305, 1590–1592
Opie LH (1993) Calcium antagonists for congestive heart failure: is it really one bridge too far to cross? Cardiovasc Drugs Ther 7:93–94
Osterloh I (1989) The safety of amlodipine. Am H J 118:1114–1120
About this article
Cite this article
Kubota, K., Pearce, G.L. & Inman, W.H.W. Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring. Eur J Clin Pharmacol 48, 1–7 (1995). https://doi.org/10.1007/BF00202163
- Calcium antagonist
- Adverse events
- prescription-event monitoring